Business Context and Reporting Period
This Form 8-K, filed on December 20, 2021, reports that Dynamics Special Purpose Corp. (DYNS) entered into a Business Combination Agreement on December 19, 2021, with Senti Biosciences, Inc. (Senti). Upon closing, Merger Sub will merge with Senti, which will survive as a wholly-owned subsidiary. The Company will change its name to "Senti Biosciences Inc." The transaction was approved by the boards of directors of both entities.
Key Financial Metrics and Transaction Structure
- Implied Equity Value: The transaction values Senti at $240,000,000 based on the exchange of DYNS Class A common stock.
- Purchase Consideration: Senti stockholders will receive DYNS Class A common stock. Outstanding Senti options will be assumed by the Company.
- PIPE Financing: Investors subscribed to purchase 6,680,000 shares of Class A Common Stock at $10.00 per share, totaling $66,800,000.
- Minimum Cash Requirement: Closing is conditioned on "Closing Available Cash" being at least $150,000,000 (after redemptions and including PIPE funds).
- Net Tangible Assets: The Company must have net tangible assets of at least $5,000,001 immediately following the merger.
- Performance-Based Earnouts:
- 1,000,000 shares if VWAP >= $15.00 for 20 of 30 trading days within 2 years of closing.
- 1,000,000 shares if VWAP >= $20.00 for 20 of 30 trading days within 3 years of closing.
Material Changes and Agreements
The filing details several material agreements executed alongside the Business Combination Agreement:
- Sponsor Support Agreement: Dynamics Sponsor LLC agreed to vote all shares in favor of the merger and waive anti-dilution protections.
- Non-Redemption Agreement: Major investors (including Morgan Stanley, T. Rowe Price, Invus, and ARK) agreed not to redeem 8,691,655 shares. In exchange, the Sponsor agreed to forfeit 965,728 Sponsor Shares, which will be cancelled and reissued to these investors as Class A Common Stock.
- Lock-Up Provisions: Senti Supporting Stockholders are subject to lock-up periods of 12 to 18 months, potentially expiring early if the stock price exceeds $12.00 for 20 of 30 trading days.
Guidance, Risks, and Conditions to Closing
The transaction is subject to customary closing conditions, including stockholder approval from both DYNS and Senti, expiration of the HSR Act waiting period, and the effectiveness of the S-4 Registration Statement. The filing includes standard forward-looking statements regarding the timing of the merger, product development, and clinical trials.
Risks and Contingencies:
- Failure to obtain stockholder approval or satisfy closing conditions.
- Termination rights if the merger is not consummated within 6 to 9 months.
- Impact of COVID-19 on Senti's business.
- Regulatory or legal proceedings that could delay or prohibit the merger.
Investor Verification Checklist
- Verify the final number of shares redeemed by public stockholders to ensure the $150,000,000 minimum cash condition is met.
- Confirm the effectiveness of the S-4 Registration Statement and the outcome of the stockholder votes for both DYNS and Senti.
- Review the full text of the Business Combination Agreement (Exhibit 2.1) for specific representations and warranties regarding Senti's financial condition and intellectual property.
- Monitor the status of the PIPE financing to ensure the $66,800,000 commitment is fulfilled at closing.
- Check for any material adverse effects (MAE) on either company between the signing date and the closing date.